Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis	idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder	Active, not recruiting	Phase 1 / Phase 2	2024-11-14		NCT04598919

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AstraZeneca	806
Baylor University	20
Icahn School of Medicine at Mount Sinai	256
International Center for Health Outcomes and Innovation Research	2
National Center for Advancing Translational Sciences (NCATS)	127
National Jewish Health	31
Yale University	458

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Baylor University Medical Center (BUMC)	Dallas	United States	2
Icahn School of Medicine at Mount Sinai	New York	United States	342
National Jewish Health	Denver	United States	72
Yale University School of Medicine	New Haven	United States	44